Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

Share Price is delayed by 15 minutes
Get Live Data
6.25    0.00 (0.00%)
Bid:
6.00
Ask:
6.50
Spread: 0.50 (8.333%)
Market Cap: £6.46m
OPTI Live PriceLast checked at - London Stock Exchange

Intraday OptiBiotix Health Share Chart

Half Yearly Results

18 Jul 2014 07:00

RNS Number : 6690M
Ducat Ventures PLC
18 July 2014
 



Ducat Ventures Plc ("Company")

 

Half Yearly Report

 

The Board of Ducat presents the unaudited historical financial information of the Company for the 6 months to 31 May 2014. 

 

Consolidated Statement of Comprehensive Income

For the six months ended 31 May 2014

 

 

 

 

Six months

 to 31 May

2014

Six months

 to 31 May

2013

 

 

 

(Unaudited)

(Unaudited)

Continuing operations

 

 

£

£

 

 

 

 

 

Revenue

 

 

-

-

Cost of Sales

 

 

-

-

 

 

 

───────

───────

 

 

 

 

 

Gross Loss

 

 

-

-

 

 

 

 

 

Administrative expenses

 

 

(57,643)

(166,453)

 

 

 

───────

───────

Operating Loss

 

 

(57,643)

(166,453)

 

 

 

 

 

Non Operating Items

 

 

 

 

Impairment of investments

 

 

-

(500,000)

Impairment of intercompany loans

 

 

-

(1,384,068)

Surplus arising on settlements with trade creditors

 

 

 

-

 

-

 

 

 

───────

───────

 

 

 

(57,643)

(2,050,521)

 

 

 

 

 

Finance Costs

 

 

-

-

 

 

 

───────

───────

Loss Before Tax

 

 

(57,643)

(2,050,521)

 

 

 

 

 

Taxation

 

 

-

-

 

 

 

───────

───────

Total comprehensive income for the period

 

 

 

(57,643)

 

(2,050,521)

 

 

 

═══════

═══════

 

 

 

 

 

Loss per share

 

 

0.006p

2.29p

 

 

 

═══════

═══════

 

 

 

 

 

 

 

 

Consolidated Balance Sheet

For the six months ended 31 May 2014

 

 

 

 

Six months

 to 31 May

2014

Six months

to 31 May

2013

 

 

 

(Unaudited)

(Unaudited)

ASSETS

 

 

£

£

 

 

 

 

 

 

 

 

 

 

CURRENT ASSETS

 

 

 

 

Trade and other receivables

 

 

10,034

49,077

Cash and cash equivalents

 

 

105,221

4,945

 

 

 

───────

───────

 

 

 

115,255

54,022

 

 

 

───────

───────

 

 

 

 

 

Total Assets

 

 

115,255

54,022

 

 

 

═══════

═══════

 

 

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

Shareholders' Equity

 

 

 

 

Called up share capital

 

 

5,742,586

5,636,083

Share premium

 

 

1,355,502

1,086,875

Share based payment reserve

 

 

27,200

27,200

Retained earnings

 

 

(7,013,950)

(6,830,754)

 

 

 

───────

───────

Total Equity

 

 

111,338

(80,596)

 

 

 

───────

───────

 

 

 

 

 

LIABILITIES

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

 

 

 

 

 

Trade and other payables

 

 

3,917

134,618

 

 

 

───────

───────

 

 

 

3,917

134,618

 

 

 

───────

───────

Total Equity and Liabilities

 

 

115,255

54,022

 

 

 

══════

═══════

 

 

 

Consolidated statement of changes in equity

For the six months ended May 2014

 

 

 

 

Called up

Share

Capital

 

 

Share

Premium

Share-

Based

Payment

Reserve

 

 

Retained

Earnings

 

 

Total

Equity

 

£

£

£

£

£

 

 

 

 

 

 

Balance at 1 August 2012

5,574,070

838,822

27,200

(4,780,233)

1,659,859

 

 

 

 

 

 

Loss for period

-

-

-

(2,050,521)

(2,050,521)

 

 

 

 

 

 

Issue of shares

62,013

248,053

-

-

310,066

 

───────

──────

──────

───────

───────

Balance at 31 May 2013

5,636,083

1,086,875

27,200

(6,830,754)

(80,596)

 

 

 

 

 

 

Loss for the period

-

-

-

(125,553)

(125,553)

 

 

 

 

 

 

Issue of shares

86,165

215,936

-

-

302,101

 

───────

──────

──────

───────

───────

Balance at 30 November 2013

5,722,248

1,302,811

27,200

(6,956,307)

95,952

 

 

 

 

 

 

Loss for the period

-

-

-

(57,643)

(57,643)

 

 

 

 

 

 

Issue of ordinary shares at £0.0004 per shares less cost

 

20,338

 

52,691

-

 

 

-

 

73,029

 

───────

──────

──────

───────

───────

Balance at 31 May 2014

5,742,586

1,355,502

27,200

(7,013,950)

113,338

 

══════

══════

══════

══════

═══════

 

 

Consolidated Statement of Cash Flows

As at 31 May 2014

 

 

 

 

 

Six months

 to 31 May

2014

Six months 

to 31 May

2013

 

 

(Unaudited)

(Unaudited)

 

 

£

£

 

 

 

 

Cash flows from operating activities

 

 

 

Loss before tax

 

(57,643)

(166,453)

(Increase)/decrease in trade and other

 receivables

 

 

291,233

 

(81,262)

Increase)/decrease in trade and other

payables

 

 

(201,548)

 

(57,416)

 

 

───────

───────

Net cash from operating activities

 

32,042

(305,131)

 

 

───────

───────

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

Issue of equity net of costs

 

73,029

310,067

Finance interest paid

 

-

-

 

 

───────

───────

Net cash from financing activities

 

73,029

310,067

 

 

───────

───────

 

 

 

 

Increase/(decrease) in cash and cash

equivalents

 

 

105,071

 

4,936

 

 

 

 

Cash and cash equivalents at the beginning of period

 

 

150

 

9

 

 

───────

───────

Cash and cash equivalents at the end of period

 

 

105,221

 

4,945

 

 

══════

═══════

 

 

 

 

 

Enquiries:

 

For further information, please contact:

Ducat Ventures plc

Nicholas Nelson

07921 522 920

Cairn Financial Advisers LLP

Liam Murray / Avi Robinson

020 7148 7900

Peterhouse Corporate Finance Ltd

Lucy Williams/ Duncan Vasey

020 7469 0936

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR FMGMNVNFGDZM
Date   Source Headline
2nd Jun 20267:00 amRNS-RInvestor presentation and SweetBiotix® Sampling
29th May 20267:00 amRNSDirector/PDMR Shareholding
28th May 20267:00 amRNSFinal Results & Notice of AGM
14th May 20267:00 amRNS-RSweetBiotix® Sampling
5th May 20262:30 pmRNSHolding(s) in Company
1st May 202612:00 pmRNSPartial Disposal of Shares in SkinBioTherapeutics
1st Apr 20267:00 amRNSTrading Update
24th Feb 20267:00 amRNSWellBiome® clinical trial on surgical outcomes
17th Feb 20267:00 amRNSStatement: SkinBioTherapeutics Announcement
21st Jan 20267:00 amRNSLarge Order and Record Early Orders for 2026
20th Jan 20267:00 amRNS-RNew Investor Website
2nd Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSHolding(s) in Company
24th Nov 20257:00 amRNSSweetBiotix Overview and Update
17th Nov 20257:00 amRNSOrder with well-known Weight Management Company
13th Oct 20253:31 pmRNSHolding(s) in Company
2nd Oct 20257:00 amRNSDirector/PDMR Shareholding
24th Sep 202512:28 pmRNSDirector/PDMR Shareholding
16th Sep 20257:00 amRNSHalf-year Report
21st Aug 20257:00 amRNSAdmission to Trading on the OTCQB Venture Market
20th Aug 20257:00 amRNSAgreement with Weight Management Company
14th Aug 20257:00 amRNSLaunch of SlimBiome in leading US brand
6th Aug 20254:08 pmRNSResult of AGM
6th Aug 20257:00 amRNSIssue of Options
28th Jul 20257:00 amRNSTrading update
30th Jun 20257:00 amRNSChange of Broker
30th Jun 20257:00 amRNSFinal Results
11th Jun 20257:00 amRNS-RSlimBiome® study in European Journal of Nutrition
23rd May 20257:00 amRNSPlacing and Issue of Warrants
20th May 20257:00 amRNSLaunch of SlimBiome products with US partner
15th Apr 20257:00 amRNSFirst order from US weight management brand
7th Apr 20255:34 pmRNSHolding(s) in Company
18th Mar 20257:00 amRNSCommercial Update
18th Feb 20257:00 amRNSLaunch of Daily Nouri FeelFull product in America
20th Jan 20257:00 amRNS-RLaunch of products on Amazon India
8th Jan 20257:00 amRNSDirectorate Change
20th Dec 202412:00 pmRNSIssue of Options
12th Dec 20242:45 pmRNSHolding(s) in Company
3rd Dec 20247:00 amRNSLaunch of Dr Morepen LightLife in India
30th Oct 20247:00 amRNSRequisition update
25th Oct 20244:29 pmRNSHolding(s) in Company
24th Oct 20247:00 amRNSTotal Voting Rights
23rd Oct 20247:00 amRNSDirectorate Change
18th Oct 20247:00 amRNSResponse to Publication of Circular by ProBiotix
10th Oct 20247:00 amRNSSlimBiome study update
27th Sep 20247:00 amRNSHalf-year Report
26th Sep 20247:00 amRNSResponse to Probiotix Health requisition notice
5th Sep 202410:32 amRNSProBiotix Health plc Fundraise
20th Aug 20247:00 amRNSCommercial update
8th Aug 202412:29 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.